These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1930 related articles for article (PubMed ID: 28360267)

  • 1. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
    Venteicher AS; Tirosh I; Hebert C; Yizhak K; Neftel C; Filbin MG; Hovestadt V; Escalante LE; Shaw ML; Rodman C; Gillespie SM; Dionne D; Luo CC; Ravichandran H; Mylvaganam R; Mount C; Onozato ML; Nahed BV; Wakimoto H; Curry WT; Iafrate AJ; Rivera MN; Frosch MP; Golub TR; Brastianos PK; Getz G; Patel AP; Monje M; Cahill DP; Rozenblatt-Rosen O; Louis DN; Bernstein BE; Regev A; Suvà ML
    Science; 2017 Mar; 355(6332):. PubMed ID: 28360267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
    Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
    Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
    Blanco-Carmona E; Narayanan A; Hernandez I; Nieto JC; Elosua-Bayes M; Sun X; Schmidt C; Pamir N; Özduman K; Herold-Mende C; Pagani F; Cominelli M; Taranda J; Wick W; von Deimling A; Poliani PL; Rehli M; Schlesner M; Heyn H; Turcan Ş
    Cell Rep Med; 2023 Nov; 4(11):101249. PubMed ID: 37883975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions.
    Dono A; Ballester LY; Primdahl D; Esquenazi Y; Bhatia A
    Curr Oncol Rep; 2021 Jan; 23(2):20. PubMed ID: 33492489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
    Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
    Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting human gliomas by single-cell RNA sequencing.
    Tirosh I; Suvà ML
    Neuro Oncol; 2018 Jan; 20(1):37-43. PubMed ID: 29016805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct tumor-TAM interactions in IDH-stratified glioma microenvironments unveiled by single-cell and spatial transcriptomics.
    Motevasseli M; Darvishi M; Khoshnevisan A; Zeinalizadeh M; Saffar H; Bayat S; Najafi A; Abbaspour MJ; Mamivand A; Olson SB; Tabrizi M
    Acta Neuropathol Commun; 2024 Aug; 12(1):133. PubMed ID: 39148129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stalled oligodendrocyte differentiation in IDH-mutant gliomas.
    Wei Y; Li G; Feng J; Wu F; Zhao Z; Bao Z; Zhang W; Su X; Li J; Qi X; Duan Z; Zhang Y; Vega SF; Jakola AS; Sun Y; Carén H; Jiang T; Fan X
    Genome Med; 2023 Apr; 15(1):24. PubMed ID: 37055795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Pathogenesis of Low-Grade Glioma.
    Bready D; Placantonakis DG
    Neurosurg Clin N Am; 2019 Jan; 30(1):17-25. PubMed ID: 30470401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
    Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
    Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
    Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
    Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
    Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
    Spitzer A; Gritsch S; Nomura M; Jucht A; Fortin J; Raviram R; Weisman HR; Gonzalez Castro LN; Druck N; Chanoch-Myers R; Lee JJY; Mylvaganam R; Lee Servis R; Fung JM; Lee CK; Nagashima H; Miller JJ; Arrillaga-Romany I; Louis DN; Wakimoto H; Pisano W; Wen PY; Mak TW; Sanson M; Touat M; Landau DA; Ligon KL; Cahill DP; Suvà ML; Tirosh I
    Cancer Cell; 2024 May; 42(5):904-914.e9. PubMed ID: 38579724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGFBP2 expression predicts IDH-mutant glioma patient survival.
    Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
    Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular categorisation of gliomas.
    Burki TK
    Lancet Oncol; 2015 Jul; 16(7):e320. PubMed ID: 26095778
    [No Abstract]   [Full Text] [Related]  

  • 17. New insights into the Immune TME of adult-type diffuse gliomas.
    Richard Q; Laurenge A; Mallat M; Sanson M; Castro-Vega LJ
    Curr Opin Neurol; 2022 Dec; 35(6):794-802. PubMed ID: 36226710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma.
    Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA
    Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-Scale Drug Screening in Patient-Derived IDH
    Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
    Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 97.